Abivax (ABVX.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $42.00.
Abivax (ABVX.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $42.00.
Piper Sandler Initiates Coverage On Abivax With Overweight Rating, Announces Price Target of $42
Piper Sandler analyst Christopher Raymond initiates coverage on Abivax (NASDAQ:ABVX) with a Overweight rating and announces Price Target of $42.
Abivax Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 162.5% Piper Sandler → $42 Initiates Coverage On → Overweight 04/11/2024 0% Morgan Stanley $15
Axsome Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley
Axsome Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley
Axsome Therapeutics Price Target Raised to $115.00/Share From $90.00 by Morgan Stanley
Axsome Therapeutics Price Target Raised to $115.00/Share From $90.00 by Morgan Stanley
Damo: The Axsome Therapeutics (AXSM.US) rating was raised from a wait-and-see shareholding rating to an increase rating, and the target price was adjusted from $90.00 to $115.00.
Damo: The Axsome Therapeutics (AXSM.US) rating was raised from a wait-and-see shareholding rating to an increase rating, and the target price was adjusted from $90.00 to $115.00.